{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02716246: Phase 2/Phase 3 Interventional Recruiting MPS IIIA
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01353222: Phase 2 Interventional Terminated Urothelial Carcinoma
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04098393: Phase 1 Interventional Active, not recruiting Hematologic Malignancies
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04387760: Phase 2 Interventional Completed SARS-CoV 2
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04445220: Phase 1/Phase 2 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cevaretigene ritoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:inlezifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03612869: Phase 2/Phase 3 Interventional Unknown status Mucopolysaccharidosis Type IIIA
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03503058: Phase 2 Interventional Completed Malaria
(2022)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE